Ignite Creation Date:
2024-05-06 @ 1:09 PM
Last Modification Date:
2024-10-26 @ 1:09 PM
Study NCT ID:
NCT03945799
Status:
TERMINATED
Last Update Posted:
2022-08-31
First Post:
2019-05-09
Brief Title:
A Multicenter Study of Anlotinib in Hepatocellular Carcinoma HCC Patients at High Risk of Post Surgery Recurrence
Sponsor:
Zhejiang University
Organization:
Zhejiang University
Study Overview
Official Title:
A Single Group Open Label Multi-center Clinical Study to Assess the Efficacy and Safety of Anlotinib in HCC Patients at High Risk of Post Surgery Recurrence
Status:
TERMINATED
Status Verified Date:
2022-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
The study has gotten preliminary results and stopped advanced
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To assess the primary effects and safety of Anlotinib in HCC patients at high risk of post surgery recurrence
Detailed Description:
Hepatocellular carcinoma is one of the most common malignant tumors in the world with high incidence and mortality Recurrence of HCC is still a great challenge and threat to the patients after resection surgery Anlotinib is a new orally administered tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor VEGFR fibroblast growth factor receptor FGFR platelet-derived growth factor receptors PDGFR and c-kit HCC patients who meet the eligibility criteria of this clinical trial will be administrated Anlotinib 12mg QD PO d1-14 21 days per cycle The disease free survival DFS overall survival OS and any adverse effect during the 8 cycles of Anlotinib treatment will be evaluated in order to assess the primary effects and safety of Anlotinib in HCC patients at high risk of post surgery recurrence
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None